

Medical Coverage Policy | Whole Gland Cryoablation of Prostate Cancer



EFFECTIVE DATE: 02|17|15

POLICY LAST UPDATED: 09|20|2023

OVERVIEW

Cryoablation, also known as cryotherapy or cryosurgery, is a procedure that attacks cancer cells using extremely cold gas. This technique can be used to treat prostate cancer by percutaneously inserting thin, needle-like cryoprobes into the prostate gland and then sending very cold gas down the cryoprobes to rapidly freeze and thaw the tissue, causing necrosis. This review evaluates evidence on the use of total (whole gland, definitive therapy) cryoablation.

This policy is applicable to Commercial Products only. For Medicare Advantage Plans, see Related Policies section.

PRIOR AUTHORIZATION

Not applicable

POLICY STATEMENT

Commercial Products

Whole gland cryoablation of the prostate may be considered medically necessary as treatment of clinically localized (organ-confined) prostate cancer when performed as initial treatment or as salvage treatment of disease that recurs following radiotherapy.

MEDICAL CRITERIA

Not applicable

BACKGROUND

Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer deaths among men in the United States, with an estimated 288,300 new cases and 34,700 deaths in 2023.¹ The diagnosis and grading of prostate cancer are performed by taking a biopsy of the prostate gland.

Treatment

Whole gland (also known as total) cryoablation is one of several methods used to treat clinically localized prostate cancer and may be considered an alternative to radical prostatectomy or external-beam radiotherapy (EBRT). Additionally, whole gland cryoablation may be used for salvage of nonmetastatic relapse following initial therapy for clinically localized disease. Using percutaneously inserted cryoprobes, the glandular tissue is rapidly frozen and thawed to cause tissue necrosis. Cryosurgical ablation is less invasive than radical prostatectomy and recovery time may be shorter. External-beam radiotherapy requires multiple treatments, whereas cryoablation usually requires a single treatment.

For individuals who are considering initial treatment for localized prostate cancer who receive whole gland cryoablation, the evidence includes systematic reviews, 2 randomized controlled trials, and many comparative and noncomparative observational studies. Relevant outcomes are overall survival (OS), disease-specific survival, symptoms, functional outcomes, quality of life, and treatment-related morbidity. High-quality data comparing cryoablation with external beam radiation therapy (EBRT), radical prostatectomy, or active surveillance are lacking, but available data have suggested similar OS and disease-specific survival rates compared with radical prostatectomy and EBRT. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome. For individuals who have salvage treatment for a

recurrence of localized prostate cancer following radiotherapy who receive whole gland cryoablation, the evidence primarily includes case series and a few retrospective studies comparing salvage cryoablation with salvage prostatectomy or brachytherapy. Relevant outcomes are OS, disease-specific survival, symptoms, functional outcomes, QOL, and treatment-related morbidity. High-quality data comparing salvage cryoablation with salvage prostatectomy or brachytherapy are lacking, though limited evidence suggests that salvage cryotherapy may be associated with better survival outcomes than prostatectomy. Men with recurrent localized prostate cancer have limited treatment options and prostatectomy can be difficult in tissue that has been irradiated. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

Regulatory Status

Cryoablation of prostate cancer is a surgical procedure that uses previously approved and available cryoablation systems; as a surgical procedure, it is not subject to regulation by the U.S. Food and Drug Administration.

COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Evidence of Coverage, Subscriber Agreement for applicable Not Medically Necessary benefits/coverage.

CODING

Commercial Products

The following code(s) is medically necessary when filed with a covered *ICD-10 Diagnosis Code(s) below;

55873 Cryosurgical ablation of the prostate (includes ultrasonic guidance and monitoring)

*ICD-10 Covered Diagnosis Code(s)

C61

C79.82

D07.5

Z85.46

RELATED POLICIES

Focal Treatments for Prostate Cancer

Medicare Advantage Plans National and Local Coverage Determinations

PUBLISHED

Provider Update, September 2023

Provider Update, January 2023

Provider Update, October 2021

Provider Update, November 2020

Provider Update, December 2019

REFERENCES:

1. National Cancer Institute Surveillance, Epidemiology and End Results Program. Cancer Stat Facts: Common Cancer Sites. Accessed June 14, 2022.
2. Gao L, Yang L, Qian S, et al. Cryosurgery would be An Effective Option for Clinically Localized Prostate Cancer: A Meta-analysis and Systematic Review. *Sci Rep.* Jun 07 2016; 6: 27490. PMID 27271239
3. Chin JL, Ng CK, Touma NJ, et al. Randomized trial comparing cryoablation and external beam radiotherapy for T2C-T3B prostate cancer. *Prostate Cancer Prostatic Dis.* 2008; 11(1): 40-5. PMID 17579613
4. Chin JL, Al-Zahrani AA, Autran-Gomez AM, et al. Extended followup oncologic outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2c-T3b). *J Urol.* Oct 2012;188(4): 1170-5. PMID 22901586

5. Donnelly BJ, Saliken JC, Brasher PM, et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. *Cancer*. Jan 15 2010; 116(2): 323-30. PMID 19937954
6. Ball AJ, Gambill B, Fabrizio MD, et al. Prospective longitudinal comparative study of early health-related quality-of-life outcomes in patients undergoing surgical treatment for localized prostate cancer: a short-term evaluation of five approaches from a single institution. *J Endourol*. Oct 2006; 20(10): 723-31. PMID 17094746
7. Elkjaer MC, Borre M. Oncological outcome after primary prostate cryoablation compared with radical prostatectomy: a single-centre experience. *Scand J Urol*. Feb 2014; 48(1): 27-33. PMID 23597178
8. Gould RS. Total cryosurgery of the prostate versus standard cryosurgery versus radical prostatectomy: comparison of early results and the role of transurethral resection in cryosurgery. *J Urol*. Nov 1999; 162(5): 1653-7. PMID10524891
9. Hubosky SG, Fabrizio MD, Schellhammer PF, et al. Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life. *J Endourol*. Dec 2007; 21(12): 1521-31. PMID 18186694
10. Xiong T, Turner RM, Wei Y, et al. Comparative efficacy and safety of treatments for localised prostate cancer: an application of network meta-analysis. *BMJ Open*. May 15 2014; 4(5): e004285. PMID 24833678
11. Robinson JW, Donnelly BJ, Siever JE, et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer: quality of life outcomes. *Cancer*. Oct 15 2009; 115(20): 4695-704. PMID19691092
12. Bahn DK, Lee F, Badalament R, et al. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. *Urology*. Aug 2002; 60(2 Suppl 1): 3-11. PMID 12206842
13. Donnelly BJ, Saliken JC, Ernst DS, et al. Prospective trial of cryosurgical ablation of the prostate: five-year results. *Urology*. Oct 2002; 60(4): 645-9. PMID 12385926
14. Ellis DS. Cryosurgery as primary treatment for localized prostate cancer: a community hospital experience. *Urology*. Aug 2002; 60(2 Suppl 1): 34-9. PMID 12206846
15. Long JP, Bahn D, Lee F, et al. Five-year retrospective, multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. *Urology*. Mar 2001; 57(3): 518-23. PMID 11248631
16. Onik G. Image-guided prostate cryosurgery: state of the art. *Cancer Control*. Nov-Dec 2001; 8(6): 522-31. PMID11807422
17. Robinson JW, Donnelly BJ, Saliken JC, et al. Quality of life and sexuality of men with prostate cancer 3 years after cryosurgery. *Urology*. Aug 2002; 60(2 Suppl 1): 12-8. PMID 12206843
18. Aus G, Pileblad E, Hugosson J. Cryosurgical ablation of the prostate: 5-year follow-up of a prospective study. *EurUrol*. Aug 2002; 42(2): 133-8. PMID 12160583
19. De La Taille A, Benson MC, Bagiella E, et al. Cryoablation for clinically localized prostate cancer using an argon-based system: complication rates and biochemical recurrence. *BJU Int*. Feb 2000; 85(3): 281-6. PMID 10671882
20. Han KR, Cohen JK, Miller RJ, et al. Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. *J Urol*. Oct 2003; 170(4 Pt 1): 1126-30. PMID 14501706
21. Prepelica KL, Okeke Z, Murphy A, et al. Cryosurgical ablation of the prostate: high risk patient outcomes. *Cancer*. Apr 15 2005; 103(8): 1625-30. PMID 15747374
22. Aus G. Cryosurgery for prostate cancer. *J Urol*. Nov 2008; 180(5): 1882-3. PMID 18801502
23. Lian H, Guo H, Gan W, et al. Cryosurgery as primary treatment for localized prostate cancer. *Int Urol Nephrol*. Dec 2011; 43(4): 1089-94. PMID 21475948
24. Williams SB, Lei Y, Nguyen PL, et al. Comparative effectiveness of cryotherapy vs brachytherapy for localized prostate cancer. *BJU Int*. Jul 2012; 110(2 Pt 2): E92-8. PMID 22192688
25. Jones JS, Rewcastle JC, Donnelly BJ, et al. Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry. *J Urol*. Aug 2008; 180(2): 554-8. PMID 18550117
26. Tay KJ, Polascik TJ, Elshafei A, et al. Primary Cryotherapy for High-Grade Clinically Localized Prostate Cancer: Oncologic and Functional Outcomes from the COLD Registry. *J Endourol*. Jan 2016; 30(1): 43-8. PMID 26414656
27. Ramsay CR, Adewuyi TE, Gray J, et al. Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation. *Health Technol Assess*. Jul 2015; 19(49): 1-490. PMID 26140518

28. Chin JL, Pautler SE, Mouraviev V, et al. Results of salvage cryoablation of the prostate after radiation: identifying predictors of treatment failure and complications. *J Urol.* Jun 2001; 165(6 Pt 1): 1937-41; discussion 1941-2. PMID11371885
29. Robinson JW, Donnelly BJ, Coupland K, et al. Quality of life 2 years after salvage cryosurgery for the treatment of local recurrence of prostate cancer after radiotherapy. *Urol Oncol.* Nov-Dec 2006; 24(6): 472-86. PMID 17138127
30. Mouraviev V, Spiess PE, Jones JS. Salvage cryoablation for locally recurrent prostate cancer following primary radiotherapy. *Eur Urol.* Jun 2012; 61(6): 1204-11. PMID 22421081
31. Peters M, Moman MR, van der Poel HG, et al. Patterns of outcome and toxicity after salvage prostatectomy, salvage cryosurgery and salvage brachytherapy for prostate cancer recurrences after radiation therapy: a multi-center experience and literature review. *World J Urol.* Apr 2013; 31(2): 403-9. PMID 22903773
32. Chin JL, Lavi A, Metcalfe MJ, et al. Long-Term Outcomes of Whole Gland Salvage Cryotherapy for Locally Recurrent Prostate Cancer following Radiation Therapy: A Combined Analysis of Two Centers. *J Urol.* Sep 2021;206(3): 646-654. PMID 33908799
33. Wenske S, Quarrier S, Katz AE. Salvage cryosurgery of the prostate for failure after primary radiotherapy or cryosurgery: long-term clinical, functional, and oncologic outcomes in a large cohort at a tertiary referral centre. *EurUrol.* Jul 2013; 64(1): 1-7. PMID 22840351
34. Williams AK, Martinez CH, Lu C, et al. Disease-free survival following salvage cryotherapy for biopsy-proven radio-recurrent prostate cancer. *Eur Urol.* Sep 2011; 60(3): 405-10. PMID 21185115
35. Ng CK, Moussa M, Downey DB, et al. Salvage cryoablation of the prostate: follow up and analysis of predictive factors for outcome. *J Urol.* Oct 2007; 178(4 Pt 1): 1253-7; discussion 1257. PMID 17698104
36. Ismail M, Ahmed S, Kastner C, et al. Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. *BJU Int.* Oct 2007; 100(4): 760-4. PMID 17662081
37. Friedlander DF, Gu X, Prasad SM, et al. Population-based comparative effectiveness of salvage radical prostatectomy vs cryotherapy. *Urology.* Mar 2014; 83(3): 653-7. PMID 24581527
38. National Comprehensive Cancer Network. Prostate Cancer. Version 4.2022.https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf Accessed June 15, 2022.
39. American Urological Association (AUA). Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. 2022;<https://www.auanet.org/documents/Guidelines/PDF/Localized%20Prostate%20Cancer%20Guideline%20050922.pdf> Accessed June 15, 2022.
40. Fenton JJ, Weyrich, MS, Durbin S, et al. U.S. Preventive Services Task Force. Evidence Summary for Prostate Cancer Screening. <https://www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/prostate-cancer-screening>. Accessed June 15, 2022.
41. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Cryosurgery of Prostate(230.9). 2001; <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=123&ncdver=1&bc=AAAAQAAAAAAA&>. Accessed June 15, 2022.

CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

